Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This review discusses lesser-known concerns in transgender dermatology, including neovaginal issues, neoplastic and autoimmune conditions, and the effects of unapproved injectable substances, but reports no new clinical findings.

In a testosterone-induced mouse model, this study found that exosomes from injectable Platelet-Rich Fibrin (i-PRF) significantly reduced inflammation, oxidative stress, and apoptosis, while enhancing hair regeneration, with the greatest improvements seen when combined with minoxidil, suggesting potential as a novel treatment for androgenetic alopecia.

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

This review discusses developments in testosterone therapy, including the shift towards transdermal therapies and long-acting injectables, but reports no new clinical findings; emerging therapies are in development.

In this case report, a patient with pseudovaginal perineoscrotal hypospadias due to 5α-reductase deficiency presented gender dysphoria, and after genomic sequencing confirmation, injectable testosterone undecanoate treatment successfully developed desired male secondary sexual characteristics.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This review examines existing research on transdermal testosterone for treating hypoactive sexual desire disorder, suggesting it improves female sexual function with minimal side effects but highlights the need for more long-term safety data.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

This study found that an oral testosterone formulation normalized serum testosterone levels and significantly reduced SHBG in men with experimentally induced hypogonadism after nine days of treatment, suggesting potential efficacy for testosterone deficiency.

This study systematically reviewed the use of topical testosterone products such as creams, gels, and patches, finding they effectively raise serum testosterone but pose significant systemic risks like acne and gynecomastia, necessitating careful medical oversight.

This review discusses the use of anabolic-androgenic steroids in sports and outlines current methods for detecting urinary steroid doping, particularly testosterone, but reports no new experimental findings.

This study found that testosterone therapy improved physical performance and strength in older men with low testosterone over 36 months, whether administered alone or with finasteride.

This review discusses the safety of testosterone therapy for postmenopausal women and concludes that, aside from hirsutism and acne, it appears safe at physiological doses for several years, though more long-term studies are needed.

This study found that testosterone replacement, with or without finasteride, did not lead to significant cognitive improvements over 36 months in healthy older men without prior cognitive impairment.

This case report describes the first instance of facial and oral mucosal hyperpigmentation and acanthosis nigricans linked to testosterone therapy in a patient with idiopathic hypogonadotropic hypogonadism.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This study suggests that finasteride at doses of 5 mg/kg BW or higher may adversely affect spermatogenesis and male fertility in NMRI mice.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This review refutes several myths about testosterone therapy in women and suggests that testosterone is beneficial for both physical and mental health, though its safety in women continues to be researched.

This study found that the GGC repeat length significantly influenced testosterone levels in oral contraceptive users from high-risk breast cancer families, and homozygosity for short alleles may be linked to increased breast cancer risk.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

Testosterone's role in women's sex drive is unclear and needs more research, as low levels don't always mean less sexual interest and high levels can cause side effects.

This review concluded that for women, the benefits of testosterone implants are outweighed by risks, with possible higher rates of irreversible adverse effects than previously reported.